Chen S - Search Results

1

Computational-aided rational mutation design of pertuzumab to overcome active HER2 mutation S310F through antibody-drug conjugates.

Bai X, Xu L, Wang Z, Zhuang X, Ning J, Sun Y, Wang H, Guo Y, Xu Y, Guo J, Chen S, Pan L. Bai X, et al. Among authors: chen s. Proc Natl Acad Sci U S A. 2025 Jan 7;122(1):e2413686122. doi: 10.1073/pnas.2413686122. Epub 2024 Dec 30. Proc Natl Acad Sci U S A. 2025. PMID: 39793038

2

Structure-Guided and Phage-Assisted Evolution of Therapeutic Antibodies to Reverse On-Target Point Mutation-Mediated Resistance.

Zhuang X, Chen S, Pan L. Zhuang X, et al. Among authors: chen s. Methods Mol Biol. 2024;2793:41-54. doi: 10.1007/978-1-0716-3798-2_3. Methods Mol Biol. 2024. PMID: 38526722

3

Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance.

Zhuang X, Wang Z, Fan J, Bai X, Xu Y, Chou JJ, Hou T, Chen S, Pan L. Zhuang X, et al. Among authors: chen s. Nat Commun. 2022 Jul 30;13(1):4431. doi: 10.1038/s41467-022-32159-6. Nat Commun. 2022. PMID: 35907884 Free PMC article.

4

Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).

Pan LQ, Wang HB, Lai J, Xu YC, Zhang C, Chen SQ. Pan LQ, et al. Biomaterials. 2013 Dec;34(36):9115-23. doi: 10.1016/j.biomaterials.2013.08.020. Epub 2013 Aug 24. Biomaterials. 2013. PMID: 23981355

5

Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.

Wei X, Yang X, Zhao W, Xu Y, Pan L, Chen S. Wei X, et al. Among authors: chen s. Bioconjug Chem. 2017 Aug 16;28(8):2180-2189. doi: 10.1021/acs.bioconjchem.7b00327. Epub 2017 Aug 1. Bioconjug Chem. 2017. PMID: 28697305

6

Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1.

Lai J, Wang Y, Wu SS, Ding D, Sun ZY, Zhang Y, Zhou J, Zhou Z, Xu YC, Pan LQ, Chen SQ. Lai J, et al. Biomaterials. 2018 Sep;178:158-169. doi: 10.1016/j.biomaterials.2018.06.017. Epub 2018 Jun 15. Biomaterials. 2018. PMID: 29933102

7

High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates.

Liu W, Zhao W, Bai X, Jin S, Li Y, Qiu C, Pan L, Ding D, Xu Y, Zhou Z, Chen S. Liu W, et al. Among authors: chen s. Eur J Pharm Sci. 2019 Jun 15;134:81-92. doi: 10.1016/j.ejps.2019.04.015. Epub 2019 Apr 13. Eur J Pharm Sci. 2019. PMID: 30986472

8

The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein.

Shen Y, Li YM, Zhou JJ, Zhou Z, Xu YC, Zhao WB, Chen SQ. Shen Y, et al. Int J Mol Sci. 2019 Aug 12;20(16):3912. doi: 10.3390/ijms20163912. Int J Mol Sci. 2019. PMID: 31408937 Free PMC article.

9

Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab.

Zhang Y, Wu S, Zhuang X, Weng G, Fan J, Yang X, Xu Y, Pan L, Hou T, Zhou Z, Chen S. Zhang Y, et al. Among authors: chen s. Onco Targets Ther. 2019 Dec 30;12:11597-11608. doi: 10.2147/OTT.S232912. eCollection 2019. Onco Targets Ther. 2019. PMID: 31920346 Free PMC article.

10

Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1.

Qiu CX, Bai XF, Shen Y, Zhou Z, Pan LQ, Xu YC, Zhao WB, Chen SQ. Qiu CX, et al. Bioconjug Chem. 2020 Dec 16;31(12):2767-2778. doi: 10.1021/acs.bioconjchem.0c00548. Epub 2020 Nov 25. Bioconjug Chem. 2020. PMID: 33237767

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88,038 results

Search Page

Filters